查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985820

月經症候群（PMS）治療市場：依治療方法、產品類型和最終用戶分類－2026-2032年全球市場預測

Premenstrual Syndrome Treatment Market by Treatment Type, Product Form, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，月經症候群 (PMS) 治療市場價值為 18.7 億美元，預計到 2026 年將成長至 19.6 億美元，複合年成長率為 5.05%，到 2032 年將達到 26.5 億美元。

主要市場統計數據
基準年 2025 18.7億美元
預計年份：2026年 19.6億美元
預測年份 2032 26.5億美元
複合年成長率 (%) 5.05%

對不斷演變的臨床複雜性、患者期望和護理路徑進行全面概述，這些因素共同塑造了月經症候群 (PMS) 的治療策略。

月經症候群（PMS）的症狀複雜多樣，包括身體不適、情緒障礙和功能障礙，需要多學科協作治療。近年來，臨床研究的進展揭示了荷爾蒙週期、神經傳導物質調節和心理社會因素之間的病理學聯繫。同時，患者越來越希望獲得能夠最大限度減少對日常生活影響的個人化干預措施。因此，目前的治療方案更加多元化，結合了行為療法、營養補充劑和成熟的藥物療法，旨在解決一系列症狀，而非僅僅針對單一症狀。

數位科技的應用推動了快速變革，透過引入個人化治療方法和綜合護理模式，正在重塑月經症候群 (PMS) 的治療。

經月經症候群 (PMS) 的治療格局正在經歷一場變革，這主要得益於技術創新、對個人化照護的重新重視以及臨床和消費者健康模式的融合。數位療法和遠端醫療平台能夠提供遠距認知行為療法和系統化的生活方式指導，從而擴大非機能性食品療法的覆蓋範圍，並有助於提高長期治療的依從性。同時，營養保健品科學和製劑技術的進步正在提高膳食補充劑的生物利用度和標準化程度，使其成為綜合護理計劃中可靠的輔助工具。

評估美國關稅到 2025 年對月經症候群 (PMS) 治療供應鏈的韌性、籌資策略和取得趨勢的累積影響。

美國關稅政策在2025年之前的變化正在對月經症候群（PMS）治療藥物的供應鏈和成本結構產生顯著影響。對於依賴進口活性藥物成分、特殊輔料和營養保健成分的產品而言，這種影響尤其明顯。為此，製造商和經銷商正試圖透過審查籌資策略、優先考慮供應商多元化以及加快庫存最佳化來降低額外進口關稅帶來的風險。這些營運調整通常包括盡可能暫時轉向國內供應商，以及重新談判供應商協議以承擔或轉嫁額外的接收成本。

關鍵的細分洞察揭示了治療類型、最終用戶趨勢和產品形式偏好如何相互交織，從而影響 PMS 護理中治療方法的採用和交付。

對治療細分市場的詳細分析突顯了治療方法選擇、護理環境和產品形式如何相互交織，並影響臨床應用和患者體驗。就治療方法類型而言，認知行為療法和結構化生活方式管理等非藥物療法在早期療育路徑中發揮著日益重要的作用。同時，營養補充品佔據著一個重要且獨特的市場區隔。基於胺基酸衍生物、草藥萃取物以及維生素和礦物質的補充劑各有其實證依據和監管要求，這些因素會影響臨床醫生的接受度和患者的信任度。對於中度至重度症狀，按藥物類別分類的藥物治療仍然至關重要，其中口服避孕藥、GABA類似物和選擇性血清素再回收抑制劑構成了臨床實踐中常用治療方法的基礎。

區域趨勢和差異化的戰略軌跡正在塑造美洲、歐洲、中東、非洲和亞太地區的治療重點和取得模式。

區域趨勢揭示了美洲、歐洲、中東、非洲和亞太地區在臨床實踐規範、法規環境和分銷基礎設施等方面存在不同的戰略重點。在美洲，成熟的醫療模式以藥物和非藥物治療相結合為特徵，而私人和公共保險公司在處方藥清單和報銷中納入附加療法的考慮進一步強化了這一模式。這種情況有助於產生證據，證明具有功能性益處和成本效益的治療路徑能夠減少後續藥物的使用。

PMS治療生態系統中企業的競爭考察和策略洞察：優勢、合作機會、監管差異化因素以及差距識別

在月經症候群 (PMS) 治療領域，競爭地位更取決於產品組合的深度、證據的可靠性和跨通路夥伴關係，而非單一產品的突破性進展。在荷爾蒙和神經調節藥物領域擁有成熟產品組合的製藥公司，透過將臨床試驗結果與真實世界的用藥依從性計畫以及與臨床醫生的合作相結合，保持其優勢。同時，能夠證明其原料來源穩定、批次間品質一致性以及臨床級配方能力的專業營養補充劑生產商和合約開發公司，對臨床醫生和大規模經銷商的吸引力也日益增強。從遠距治療平台到數位化症狀追蹤器，技術驅動型供應商正透過整合行為介入、臨床監督和數據收集等功能來脫穎而出。

為行業領導者提供可操作的策略建議，以加速採用、最佳化獲取途徑，並在 PMS 治療和服務交付中提供綜合價值。

產業領導者應優先考慮一系列合作舉措，以加速產品應用、維持市場可近性，並在臨床和商業管道中創造永續價值。首先，投資於高品質的實證研究，將介入措施與功能性結果聯繫起來，有助於增強與臨床醫生和保險公司的合作關係，並促進產品融入日常診療流程。其次，開發可與藥物治療和補充劑產品聯合使用的互通性數位工具和遠端醫療項目，有助於提高患者的用藥依從性，並支持長期療效評估。此外，還應輔以穩健的生產和供應鏈策略，以減少對單一來源進口的依賴，並增強應對力關稅和貿易政策變化的能力。

本文檔概述了一種高度透明的多方法調查方法，包括檢驗、專家檢驗和資料收集分析框架，構成了 PMS 治療分析的基礎。

本分析採用多方法研究策略，優先考慮對一級資訊來源和二級資訊來源進行檢驗和有效性檢驗。一級資訊來源包括對臨床醫生、藥房經理、採購專家和技術提供者的結構化訪談，旨在了解他們對治療效果、給藥挑戰和推廣應用促進因素的實際觀點。二級資訊來源包括同行評審的臨床文獻、監管指導文件、產品標籤和公開的臨床試驗註冊資訊，以支持對作用機制、安全性特徵和治療定位的闡述。在資料整合過程中，我們運用主題分析來識別重複出現的模式，並採用比較評估來揭示區域差異。

我們進行最終的綜合分析，將臨床趨勢、監管影響和市場趨勢結合起來，為 PMS 護理領域的相關人員制定可操作的下一步措施。

總而言之，月經症候群（PMS）治療格局的演變以向以患者為中心的綜合治療模式轉變為特徵，這種模式結合了行為療法、營養補充劑和藥物治療。臨床實務和治療方式的創新正在拓寬有效介入措施的範圍，同時也提高了實證醫學、品質和互通性的標準。政策和貿易因素凸顯了建立具有韌性的供應鏈和靈活籌資策略的必要性，而區域間法規和治療模式的差異則強調了製定個人化方案而非統一部署的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法月經症候群（PMS）治療市場

  • 非藥物治療
    • 認知行為療法
    • 生活方式管理
    • 營養補充品
      • 胺基酸衍生物
      • 草藥萃取物
      • 維生素和礦物質
  • 藥物治療

第9章：月經症候群（PMS）治療市場：依產品形式分類

  • 膠囊
  • 口服液
  • 藥片

第10章：月經症候群（PMS）治療市場：依最終用戶分類

  • 居家照護設施
  • 醫院
  • 專科診所

第11章月經症候群（PMS）治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章月經症候群（PMS）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章月經症候群（PMS）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國月經症候群（PMS）治療市場

第15章：中國月經症候群（PMS）治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4F1ADAF481D9

The Premenstrual Syndrome Treatment Market was valued at USD 1.87 billion in 2025 and is projected to grow to USD 1.96 billion in 2026, with a CAGR of 5.05%, reaching USD 2.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.87 billion
Estimated Year [2026] USD 1.96 billion
Forecast Year [2032] USD 2.65 billion
CAGR (%) 5.05%

Comprehensive contextual overview of the evolving clinical complexities patient expectations and care pathways shaping premenstrual syndrome treatment strategies

Premenstrual syndrome continues to present a complex constellation of symptoms that span physical discomfort, mood disturbance, and functional impairment, demanding multidisciplinary attention. Recent advances in clinical understanding have clarified pathophysiologic pathways that link hormonal cycling, neurotransmitter modulation, and psychosocial triggers, while patient expectations increasingly favor individualized and minimally disruptive interventions. Consequently, care pathways now reflect a broader palette of options that combine behavioral strategies, nutraceuticals, and established pharmacotherapies to address symptom clusters rather than single complaints.

Moreover, health systems and clinicians are responding to shifting patient preferences by integrating remote monitoring, stepped-care protocols, and clearer diagnostic criteria to reduce time to intervention. These trends are amplifying demand for evidence-backed therapeutic alternatives that balance efficacy, tolerability, and real-world usability. As a result, stakeholders from product developers to service providers are reframing clinical value propositions to emphasize measurable improvements in daily functioning, adherence-friendly formats, and interventions that complement rather than replace standard medical care. Taken together, these developments set the stage for more nuanced service models and commercial approaches that prioritize patient-centric outcomes and scalable delivery mechanisms.

Rapid transformative shifts driving digital enablement personalized therapeutic approaches and integrated care models reshaping premenstrual syndrome treatment

The landscape for premenstrual syndrome treatment is undergoing transformative shifts driven by technological innovation, a renewed focus on personalized care, and the convergence of clinical and consumer health paradigms. Digital therapeutics and telehealth platforms are enabling remote cognitive behavioral therapy and structured lifestyle coaching, which in turn are expanding access to non-pharmacological interventions and supporting long-term adherence. Simultaneously, advances in nutraceutical science and formulation techniques are improving the bioavailability and standardization of supplements, thereby making them more credible adjuncts within comprehensive care plans.

In parallel, pharmacological innovation is being informed by deeper insights into neuroendocrine modulation, with clinicians more readily combining established drug classes with targeted behavioral interventions to optimize benefit-risk profiles. Health systems are also experimenting with integrated care pathways that embed symptom tracking, outcome measurement, and stepped escalation protocols to better match intervention intensity to patient needs. These shifts are creating new strategic imperatives for developers and providers: investments in digital enablement, real-world evidence generation, and collaborative care frameworks are becoming essential to differentiate therapeutic offerings and to demonstrate tangible value across diverse payers and delivery settings.

Assessment of the cumulative impact of United States tariffs through 2025 on supply chain resilience procurement strategies and access dynamics for PMS treatments

Tariff policy changes in the United States through 2025 have exerted a measurable influence on the supply chains and cost structures that underpin premenstrual syndrome treatment delivery, particularly for products that rely on internationally sourced active pharmaceutical ingredients, specialty excipients, and imported nutraceutical components. Manufacturers and distributors have responded by reassessing sourcing strategies, prioritizing supplier diversification, and accelerating inventory optimization to mitigate exposure to incremental import duties. These operational adjustments have, in many cases, led to temporary reallocation of sourcing to domestic suppliers where feasible and to renegotiation of supplier agreements to absorb or pass through incremental landed costs.

At the same time, clinical service models and end users have adapted to preserve access and affordability. Hospitals and specialty clinics have tightened procurement protocols and emphasized therapeutic equivalence assessments to maintain continuity of care despite potential price movement in specific product lines. Home care models and remote dispensing have gained traction as stakeholders seek to preserve adherence while minimizing cost inflation associated with facility-based supply chains. Ultimately, the tariff environment has reinforced the importance of flexible manufacturing, transparent cost modeling, and regulatory foresight for companies engaged in developing or delivering treatments for premenstrual syndrome, prompting a strategic focus on resilience rather than short-term repricing.

Key segmentation insights revealing how treatment type end-user dynamics and product form preferences converge to determine therapeutic adoption and delivery for PMS care

A granular view of treatment segmentation highlights how therapeutic choices, care settings, and product formats intersect to shape clinical adoption and patient experience. When considering treatment type, non-pharmacological approaches such as cognitive behavioral therapy and structured lifestyle management play an increasingly central role in early intervention pathways, while nutritional supplements occupy a distinct niche where formulation matters; supplements based on amino acid derivatives, herbal extracts, and vitamins and minerals each present unique evidence requirements and regulatory considerations that influence clinician acceptance and patient trust. Conversely, pharmacological treatments organized by drug class remain essential for moderate to severe symptom profiles, with combined oral contraceptives, GABA analogs, and selective serotonin reuptake inhibitors forming the backbone of therapeutic regimens used in clinical practice.

End-user contexts further modulate preference and delivery: home care settings favor interventions that enable self-administration and remote support, hospitals prioritize acute symptom control and multidisciplinary coordination, and specialty clinics often serve as centers for tailored regimens and advanced therapeutic sequencing. Product form influences adherence and formulation strategy; capsules, oral liquids, and tablets each present distinct advantages related to dosing flexibility, palatability, and stability, which in turn inform product development priorities. Integrating these segmentation dimensions reveals that successful offerings will address evidence thresholds for specific therapeutic classes while aligning product form and delivery models to the operational realities of home care, hospital, and specialty clinic settings.

Regional dynamics and differentiated strategic trajectories across the Americas Europe Middle East & Africa and Asia-Pacific that shape treatment priorities and access models

Regional dynamics reveal differentiated strategic priorities driven by clinical practice norms, regulatory environments, and distribution infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, care models are characterized by a mature mix of pharmacological and non-pharmacological adoption augmented by private and public payer considerations that influence formulary placement and reimbursement of adjunctive therapies. This context incentivizes evidence generation that demonstrates functional benefits and cost-effective care pathways that reduce downstream utilization.

Across Europe, the Middle East and Africa, fragmented regulatory frameworks and diverse payer landscapes create complex entry barriers but also enable region-specific innovation, particularly where telehealth and community-based delivery can expand reach. Local manufacturing capabilities and regulatory harmonization efforts are pivotal in determining which product forms and supplements gain traction. Meanwhile, the Asia-Pacific region combines rapidly expanding digital infrastructure with strong demand for nutraceuticals and culturally embedded herbal approaches, and this is complemented by accelerated adoption of remote care models and consumer-facing health technologies. Taken together, these regional trajectories suggest that companies must tailor regulatory strategies, evidence packages, and distribution models to the predominant clinical and payer dynamics of each geography to achieve sustainable adoption.

Competitive and strategic company insights identifying capability strengths partnership opportunities regulatory differentiators and gaps within the PMS treatment ecosystem

Competitive positioning within the premenstrual syndrome treatment ecosystem is defined less by single product breakthroughs and more by portfolio depth, evidence robustness, and cross-channel partnerships. Pharmaceutical companies with established portfolios in hormonal and neuro-modulatory classes retain advantages when they pair clinical trial outcomes with real-world adherence programs and clinician engagement. At the same time, specialist nutraceutical manufacturers and contract developers that can demonstrate consistent sourcing, batch-to-batch quality, and clinical-grade formulation are increasingly attractive to both clinicians and large-scale distributors. Technology-enabled providers-ranging from teletherapy platforms to digital symptom trackers-are differentiating through integration capabilities that link behavioral interventions with clinical oversight and data capture.

Strategic collaborations between these constituents are becoming more common, as manufacturers seek to bundle pharmacological options with digital therapeutics or evidence-based supplementation to create comprehensive care pathways. Regulatory approvals, quality certifications, and transparent supply chain practices continue to be key differentiators, and companies that invest in comparative-effectiveness research and payer engagement are better positioned to influence procurement decisions. Ultimately, competitive advantage accrues to organizations that can align clinical credibility with scalable delivery and that can adapt product and service offerings to diverse end-user settings.

Actionable strategic recommendations for industry leaders to enhance adoption optimize access and deliver integrated value across PMS therapeutic and service offerings

Industry leaders should prioritize a set of coordinated actions that accelerate adoption, preserve access, and create durable value across clinical and commercial channels. First, investing in high-quality evidence that links interventions to functional outcomes will strengthen positioning with clinicians and payers and will facilitate integration into care pathways. Second, developing interoperable digital tools and telehealth-enabled programs that can be bundled with pharmacological or supplement offerings will improve adherence and support longitudinal outcome measurement. These capabilities should be complemented by robust manufacturing and supply chain strategies that reduce dependence on single-source imports and that enhance responsiveness to tariff or trade-policy shifts.

In addition, organizations ought to pursue cross-sector partnerships that combine pharmaceutical expertise, nutraceutical formulation, and digital engagement to offer multi-modal therapeutic packages that reflect real-world patient needs. Strategic market entry should be regionally tailored, with regulatory and reimbursement strategies aligned to local health system dynamics. Finally, operationalizing patient-centric product design-through adaptable dosing formats, palatable oral liquids, and user-friendly capsule or tablet options-will increase acceptance across home care, hospital, and specialty clinic settings, thereby improving real-world uptake and clinical impact.

Transparent multi-method research methodology outlining data collection triangulation expert validation and analytical frameworks underpinning the PMS treatment analysis

This analysis was developed using a multi-method research approach that prioritized triangulation and validation across primary and secondary sources. Primary inputs included structured interviews with clinicians, pharmacy leaders, procurement specialists, and technology providers to capture frontline perspectives on therapeutic effectiveness, delivery challenges, and adoption drivers. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, product labeling, and publicly available clinical trial registries to corroborate mechanism-of-action, safety profiles, and therapeutic positioning. Data synthesis relied on thematic analysis to identify recurring patterns and on comparative assessment to surface region-specific distinctions.

Analytical rigor was maintained through iterative validation cycles, wherein preliminary findings were reviewed with domain experts to refine assumptions and to identify potential bias. Supply chain and policy impacts were assessed through scenario analysis that considered tariff-related logistics, sourcing alternatives, and procurement responses, with attention to operational feasibility. The methodology emphasizes transparency in source attribution and contextual caveats so that stakeholders can judge the applicability of findings to their strategic questions and regional contexts.

Concluding synthesis integrating clinical trends regulatory influences and commercial signals to define pragmatic next steps for stakeholders in PMS care

In synthesis, the evolving landscape for premenstrual syndrome treatment is defined by a move toward integrated, patient-centered care that blends behavioral, nutraceutical, and pharmacological approaches. Clinical and delivery innovations are expanding the range of viable interventions while also raising the bar for evidence, quality, and interoperability. Policy and trade factors have highlighted the need for resilient supply chains and adaptive procurement strategies, and regional differences in regulation and care models underscore the necessity of tailored plans rather than one-size-fits-all rollouts.

Looking ahead, stakeholders who invest in rigorous outcome measurement, who build flexible product portfolios spanning capsules, oral liquids, and tablets, and who leverage digital platforms to support adherence will be best positioned to meet clinician and patient expectations. Collaboration across pharmaceutical, nutraceutical, and digital health domains will be essential to convert clinical promise into practical, scalable care. Ultimately, the most successful strategies will be those that balance scientific credibility with operational agility and that deliver demonstrable improvements in daily functioning for individuals affected by premenstrual syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Premenstrual Syndrome Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological Treatment
    • 8.1.1. Cognitive Behavioral Therapy
    • 8.1.2. Lifestyle Management
    • 8.1.3. Nutritional Supplements
      • 8.1.3.1. Amino Acid Derivatives
      • 8.1.3.2. Herbal Extracts
      • 8.1.3.3. Vitamins & Minerals
  • 8.2. Pharmacological Treatment

9. Premenstrual Syndrome Treatment Market, by Product Form

  • 9.1. Capsule
  • 9.2. Oral Liquid
  • 9.3. Tablet

10. Premenstrual Syndrome Treatment Market, by End User

  • 10.1. Home Care Settings
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Premenstrual Syndrome Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Premenstrual Syndrome Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Premenstrual Syndrome Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Premenstrual Syndrome Treatment Market

15. China Premenstrual Syndrome Treatment Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Bayer AG
  • 16.6. Eli Lilly and Company
  • 16.7. GlaxoSmithKline plc
  • 16.8. Johnson & Johnson Services, Inc.
  • 16.9. Novartis AG
  • 16.10. Pfizer Inc.
  • 16.11. Sanofi S.A.
  • 16.12. Sun Pharmaceutical Industries Ltd.
  • 16.13. Teva Pharmaceutical Industries Ltd.
  • 16.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)